NMN and NR: what oral supplements have shown

The most useful question about a supplement is simple: what would you like it to improve? NMN and NR research offers several clues, from muscle metabolism to walking in vascular disease. This review covers oral preparations and research available through September 22, 2026. [1] [2] [4] [5] [14]

The route matters too. Capsule studies address a different intervention from research on NAD infusions.

NMN and NR side by side

The trials below generally compare one ingredient with placebo or other care. Reading them side by side is useful, but differences between separate trials do not establish whether NMN is better than NR.

The study sizes and results behind this comparison are set out below. [2] [4] [5] [6]

What an NAD increase measures

Nicotinamide adenine dinucleotide, or NAD, participates in cellular energy reactions and processes that maintain cell function. NR and NMN are precursors: starting materials the body can use in NAD-related pathways. They are distinct compounds, not alternative names for NAD or automatically interchangeable products. [1] [11]

In a 2018 randomized crossover trial, 30 healthy middle-aged and older adults entered a comparison of NR chloride and placebo, and 24 completed both six-week periods. In a crossover study, the same participant receives both interventions at different times. NR increased NAD in circulating immune cells. That demonstrated a biological effect under the trial conditions. Exploratory cardiovascular findings did not establish prevention of heart attacks. [1]

A biomarker measures a step in a longer proposed chain: a supplement must be absorbed or metabolized, affect the relevant tissue and ultimately improve something that matters to a person. A change in the first steps does not establish the last.

Even “NAD level” needs a sample type. Whole blood, a specific group of blood cells and muscle are different measurements. An increase in one cannot be assumed to occur throughout the body. A higher number also does not by itself show that someone was deficient, that the new value is optimal or that repeated supplementation will produce lasting benefit. [1] [4]

Five trials with different answers

Insulin sensitivity describes how well tissues respond to insulin. Prediabetes means glucose levels are elevated without reaching the diabetes range. The favorable NMN muscle finding and the null NR result in men do not cancel each other out: the compounds and participants differed. Together, they argue for testing specific uses rather than presenting the entire category as an established metabolic treatment. [2] [3]

The walking result was positive by an exploratory rule

Peripheral artery disease limits blood flow to the limbs. In NICE, the NR group's change in six-minute walking distance at six months was 17.6 meters better than placebo. The trial had specified a one-sided significance threshold of 0.10; the comparison's P value was 0.08, so it met that exploratory criterion. [4]

A one-sided test focuses on a difference in a specified direction; a two-sided test considers differences in either direction. This trial's design accepts more uncertainty than the conventional two-sided 0.05 threshold used in many confirmatory trials. It is a preliminary positive finding that needs confirmation. Adding resveratrol did not improve the result. The finding applies to people with peripheral artery disease, not healthy adults seeking more energy. [4]

A publisher correction restored an omitted trial registration number; it did not change the reported results. [4]

The memory and exercise trials sharpen the distinction

Amnestic mild cognitive impairment involves memory difficulties. In the 2026 pilot, 42 people completed the trial: 22 assigned to NR and 20 to placebo. Blood NAD approximately doubled in the NR group, but cognition, total blood flow to the brain and blood pressure did not improve over 12 weeks. Exploratory findings in individual brain regions may guide future studies; they do not overturn the null primary cognitive outcome or demonstrate dementia prevention. [5]

The Friedreich's ataxia trial studied a different problem. This inherited neurological disease affects function and exercise capacity. The 66 participants included children and adults aged 10–40; half were children. After 12 weeks, NR plus individualized exercise improved peak exercise capacity, measured by peak oxygen uptake during an exercise test, compared with placebo and no exercise. [14]

The crucial comparisons are with the individual components. NR alone did not show a significant advantage over control, and the combination was not significantly better than exercise alone. It would therefore be inaccurate to assign the entire combined effect to NR or conclude that the supplement added a demonstrated benefit to exercise. This disease-specific study is not evidence of healthier aging in the general population. [14]

What the broader metabolic review found

A 2026 systematic review of oral NMN and related preparations included 15 trials lasting 14 days to 24 weeks. The pooled results did not show convincing improvements in weight, fasting glucose, HbA1c—a measure of longer-term glucose control—or blood lipid measures. A small reduction in diastolic blood pressure, the lower reading, did not establish a broad metabolic benefit. [6]

The review combined different preparations and study settings. A pooled average is useful context, but it does not make those products or populations identical. These short studies also cannot determine whether a possible effect lasts for years.

Short-term tolerance and product quality answer different questions

Several short studies found no major treatment-related safety signal. That is useful within the exposure studied. Trials with dozens of participants followed for weeks are less able to reveal rare harms or consequences of use over years. They do not prove that the supplements are harmful; they leave long-term benefit and risk uncertain. [1] [3] [5] [6]

For a healthy person, an uncertain benefit has to be considered alongside possible medicine interactions, unwanted effects and ongoing cost. A study of one well-defined preparation does not validate every blend sold under the same ingredient name. Other ingredients can make it harder to identify the cause of either a benefit or a symptom. Identity and purity are product-quality questions; neither demonstrates disease prevention.

Review the actual product label and the full medicine and supplement list with a clinician or pharmacist before use. This is especially relevant during treatment for a medical condition, pregnancy or breastfeeding, or preparation for surgery. FDA guidance emphasizes that supplements can interact with medicines and should not replace prescribed treatment. [8]

What the US NMN decision changed

In its September 2025 response to a citizen petition, the US Food and Drug Administration (FDA) reversed its earlier position that NMN was excluded from the dietary supplement definition under a rule concerning ingredients investigated as drugs. Earlier food or supplement marketing was central to the decision. The FDA concluded that this particular exclusion did not apply to NMN. [7]

The response did not approve NMN for longevity or approve every NMN product. Other requirements remained, including applicable obligations for new dietary ingredients. Identity, manufacturing, labeling and safety requirements still matter. FDA does not approve dietary supplements for safety and effectiveness before they are sold. [7] [8]

NR has a separate US regulatory history. The FDA's August 3, 2016 response to GRAS Notice No. 635 concerned nicotinamide riboside chloride in specified conventional-food uses. GRAS means “generally recognized as safe” for the intended use. The agency's “no questions” response to the notifier's safety conclusion was not approval of an anti-aging treatment and did not substantiate anti-aging health claims. [9]

For any regulatory claim, the useful details are the chemical form, product category, intended use, jurisdiction and actual decision. A logo or the phrase “FDA recognized” does not supply those details.

What the European documents establish

US decisions do not determine status in the European Union, including Czechia. Nicotinamide riboside chloride received an EU novel-food authorization in 2020, with uses and specifications amended in 2022. The authorization applies to specified uses and conditions. Its entry appears in the Union list consolidated through August 10, 2026. Food authorization answers a regulatory question; treatment claims need clinical evidence. [10] [13]

NMN has a different history. An October 11, 2022 consultation through the Czech competent authority classified the assessed NMN ingredient as a novel food. That is a classification, not a market authorization. [12]

The European Food Safety Authority (EFSA) published a favorable safety opinion on May 11, 2026, amended July 8, for a particular chemically synthesized beta-NMN preparation under proposed adult supplement conditions, excluding pregnancy and breastfeeding. It evaluated safety and nutrient availability, not the effectiveness of claimed health benefits. [11]

An EFSA scientific opinion and a European Commission authorization are separate steps. The August 10, 2026 consolidated Union list included NR chloride but no NMN entry. That dated list does not provide blanket permission for NMN products or settle the status of any later authorization. A current product-specific check is needed. A product's EU or Czech market eligibility depends on the applicable authorization and its conditions; a US decision or favorable EFSA opinion alone cannot establish it. [11] [12] [13]

What to take into a consultation

Start with whether the participants and outcome match your goal. Muscle insulin sensitivity, walking and memory are different questions. The promising findings deserve further research; the memory trial also shows why a higher blood NAD level may not translate into better function.

For a supplement combined with exercise, ask whether it added to exercise alone. For fatigue or memory concerns, first investigate the possible cause. A decision can then account for the exact preparation, medicines, cost and how a useful result would be judged. [8] [14]

Three questions for a clinician or pharmacist

1. Which outcome am I trying to improve, and did a controlled trial of this ingredient improve it in people similar to me?

2. What do my medicines, health conditions and the exact product formulation change about the possible risks and alternatives?

3. How would we judge a meaningful benefit or a reason to stop, and what does the relevant regulatory document actually permit?